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Résumé en
anglais
A transient increase in skin blood flow in response to an innocuous local pressure
application, defined as pressure-induced vasodilatation (PIV), delays the occurrence
of ischaemia, suggesting a protective feature against applied pressure. The PIV
response depends on capsaicin-sensitive nerve fibres and calcitonin gene-related
peptide (CGRP) has been shown to be involved. In these fibres, CGRP coexists with
pituitary adenylate cyclase-activating polypeptide (PACAP). Three distinct receptors
mediate the biological effects of PACAP: VPAC1 and VPAC2 receptors binding with
the same affinity for PACAP and vasoactive intestinal peptide and PAC1 receptors
showing high selectivity for PACAP. Because the receptors are widely expressed in
the nervous system and in the skin, we hypothesized that at least one of them is
involved in PIV development. To verify this hypothesis, we used [D-p-Cl-
Phe(6),Leu(17)]-VIP (nonspecific antagonist of VPAC1/VPAC2 receptors), PG 97-269
(antagonist of VPAC1 receptors), PACAP(6-38) (antagonist of VPAC2/PAC1
receptors) and Max.d.4 (antagonist of PAC1 receptors) in anaesthetized rodents. The
blockade of VPAC1/VPAC2, VPAC1 or VPAC2/PAC1 receptors eliminated the PIV
response, whereas PAC1 blockade had no effect, demonstrating an involvement of
VPAC1/VPAC2 receptors in PIV development. Moreover, endothelium-independent
and -dependent vasodilator responses were unchanged by the VPAC1/VPAC2
antagonist. Thus, the absence of a PIV response following VPAC1/VPAC2 blockade
cannot be explained by any dysfunction of the vascular smooth muscle or endothelial
vasodilator capacity. The involvement of VPAC1/VPAC2 receptors in the
development of PIV seems to imply a series relationship in which each receptor type
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